V ascular endothelial cells constitute vascular endothelium as an important interface between circulating blood and blood vessels. The endothelium regulates vascular tone by releasing endothelium-derived relaxing factors and endothelium-derived contracting factors (EDCFs), which respond to substances present in the blood and to shear stress generated by blood flow.
V ascular endothelial cells constitute vascular endothelium as an important interface between circulating blood and blood vessels. The endothelium regulates vascular tone by releasing endothelium-derived relaxing factors and endothelium-derived contracting factors (EDCFs), which respond to substances present in the blood and to shear stress generated by blood flow. [1] [2] [3] [4] Endothelium-derived relaxing factors and EDCFs regulate the contractility of vascular smooth muscle cells by modulating the Ca 2+ concentration in opposite directions. 5 Endothelium-dependent contractions are less well discussed, but have been correlated with endothelial dysfunction in hypertension. 6, 7 Endothelial dysfunction in hypertension has been characterized by enhanced endothelium-dependent contraction and decreased endothelium-dependent relaxation. [6] [7] [8] Acetylcholine (ACh) can trigger the release of EDCFs under pathophysiological conditions, and this allows the influx of extracellular Ca 2+ through nonselective cation channels, but the mechanism by which the intracellular Ca 2+ ([Ca 2+ ] i ) signal is regulated in response to ACh is still unknown. 9, 10 Recently, it has been shown that the Ca 2+ influx mediated by members of the TRP (transient receptor potential) family plays a crucial role in modulating vascular tone.
11,12 TRPV4 (TRP vanilloid 4) is a nonselective cation channel that is mainly expressed in endothelial cells, but its expression has also been demonstrated in other cell types. [13] [14] [15] TRPV4 was originally identified as a sensor of hypotonic cell swelling in the central nervous system. 16 It has been reported that TRPV4 is gated by a variety of physical and chemical stimuli, including temperature, shear stress, 4-phorbol 12,13-didecanoate, and mechanical stretch. [17] [18] [19] [20] TRPV4 is also triggered by arachidonic acid and epoxyeicosatrienoic acid, 21, 22 and GSK1016790A can trigger TRPV4 pharmacologically. 23 Previously, we and other groups have shown that activation of TRPV4 modulates endothelial Ca 2+ influx and then triggers vascular relaxation through the release of nitric oxide and activation of small-and intermediate-conductance Ca 2+ -activated K + channels. 24, 25 TRPV4 plays a critical role in ACh-induced vascular relaxation in systemic arteries. 26 Although vascular relaxation is a widely-recognized response to endothelial TRPV4 channel activation, emerging data show that TRPV4 contributes to vascular contraction. 27 However, TRPV4 has not been shown to be involved in mediating endotheliumdependent contraction in the aortas of mice with hypertension, and the molecular mechanism of its involvement in this process has not been determined.
In the present study, we tested the hypothesis that the TRPV4 channel plays a role in endothelium-dependent contraction in hypertension. Our results showed that TRPV4 regulates endothelium-dependent contraction in aortas from hypertensive mice through activation of cytosolic cPLA 2 (phospholipase A 2 ) and COX2 (cyclooxygenase 2). We also found that prostaglandin F 2α (PGF 2α ) is the EDCF induced by TRPV4 activation. Our study reveals a novel role for TRPV4 in hypertension and for TRPV4-mediated Ca 2+ influx in the activation of cPLA 2 and COX2.
Methods

Animals
All of the experiments were conducted in conformity with the Guide for Animal Care and Use of Laboratory Animals published by the US National Institute of Health and the Animal Care and Use Committee guidelines of Jiangnan University. TRPV4 knockout (KO; TRPV4 −/− ) mice were obtained from Dr Makoto Suzuki (Jichi Medical School, Tochigi, Japan).
28 TRPV4-KO and wild-type (WT) male mice at 6 to 8 weeks of age were used in this study. In some experiments, mice were made hypertensive by (1) the addition of the NO synthase inhibitor N ω -nitro-l-arginine (L-NNA) to the drinking water (0.5 g/L; 7-day duration) and normal drinking water as vehicle control 29 ; (2) delivery of angiotensin II (Ang II) in 0.9% NaCl and delivery of 0.9% NaCl as vehicle control at an infusion rate of 500 ng·kg −1 ·min −1 for 14 days; and (3) fed with high-salt diet (HSD; 8% NaCl) for >3 weeks 30 and normal-salt diet (NSD; 0.3% NaCl) was taken as control. Systolic and diastolic blood pressures were recorded by tail-cuff plethysmography (NIPB-2 noninvasive blood pressure monitor, Columbus Instruments). 29, 31 The average of 3 to 4 measurements on each day of treatment was taken as the representative pressure for each animal.
Cell Preparation and Culture
Primary mouse aortic endothelial cells (MAECs) were isolated from C57BL/6 mice and used for experiments without passage. Briefly, aortas were dissected in endothelial basal medium and incubated with type II collagenase for 8 minutes at 37°C. Detached endothelial cells were collected by centrifugation, resuspended in endothelial cell growth medium supplemented with bovine brain extract (Lonza, Walkersville, MD) and cultured in a flask at 37°C with 5% CO 2 . Nonadherent cells were removed 2 hours later. The adherent endothelial cells were cultured in endothelial cell growth medium at 37°C with 5% CO 2 for 1 to 2 days.
Statistics
Data are expressed as mean±SEM. For measurements of arterial tension, n corresponds to the number of animals per group. For other experiments, n corresponds to the number of independent replications. Statistical analysis used repeated-measures 1-way or 2-way ANOVA followed by Newman-Keuls or Bonferroni test for multiple group comparisons, respectively, using GraphPad Prism software. Differences were considered statistically significant when P<0.05.
An expanded Materials and Methods section is available in the online-only Data Supplement.
Results
TRPV4 Regulates Endothelium-Dependent Contractions in Aortas From Hypertensive Mice
First, a wire myograph was used to measure the vascular tone in mouse aorta. GSK1016790A is a synthetic compound that selectively activates TRPV4 channels. 23 Interestingly, we recorded a concentration-dependent contractile response to GSK1016790A in aortas from mice placed on HSD (8% NaCl), L-NNA intake (0.5 g/L in the drinking water) or Ang II delivery (at an infusion rate of 500 ng·kg
), but not in the control groups, with a maximal response of ≈40% to 60% of the contractile response induced by 60 mmol/L KCl ( Figure 1A and 1B). The systolic blood pressure values after HSD, L-NNA, or Ang II were measured in TRPV4-WT and TRPV4-KO mice ( Figure S1 in the online-only Data Supplement). Baseline or hypertension-induced systolic blood pressure was similar in TRPV4-KO and TRPV4-WT mice ( Figure S1 ). Removal of the endothelium eliminated the contractile response to GSK1016790A in HSD, L-NNA, and Ang II mouse aortas ( Figure 1C) . Likewise, the specificity of TRPV4-dependent contraction was confirmed by the lack of a contractile effect of GSK1016790A in the HSD, L-NNA, and Ang II TRPV4-KO groups ( Figure 1D ). GSK1016790A caused relaxations in aortas of normal TRPV4-WT mice and Ach caused less relaxant responses in aortas from normal TRPV4-KO mice ( Figure S2 ). To further explore the TRPV4-dependent contraction, we used ACh to indirectly activate TRPV4 channels. ACh (10 µmol/L) elicited pronounced contraction of 3.1±0.3 mN in intact aortic segments from HSD mice ( Figure 1E ). The contractile response to ACh (10 µmol/L) was suppressed in intact aortas isolated from HSD TRPV4-KO mice ( Figure 1F ). HC067047 (1 µmol/L), a specific TRPV4 inhibitor, also markedly reduced the vascular contraction induced by ACh (10 µmol/L) in HSD TRPV4-WT mice ( Figure S3 Figure S4B ). Together, these data demonstrate that TRPV4 regulates endothelium-dependent contractions in aortas from hypertensive mice.
Activation of cPLA 2
To assess the biochemical pathway responsible for the vascular contraction elicited by TRPV4, we investigated the action of cPLA 2 , which is responsible for generating the contractile agonist and is Ca 2+ -dependent. The HSD did not increase the expression of cPLA 2 ( Figure 2A ), but significantly increased its phosphorylation and PLA 2 activity in primary cultured MAECs (Figure 2A and 2B). We also evaluated the time course of phosphorylation of cPLA 2 protein expression and our results demonstrated that, in primary cultured MAECs from HSD mice, stimulation of TRPV4 with GSK1016790A (100 nmol/L) at different time points enhanced the phosphorylation of cPLA 2 , which was sustained for up to 20 minutes ( Figure 2C ). But in primary cultured MAECs from NSD mice, the phosphorylation of cPLA 2 was not changed at the different time points ( Figure 2D ). Furthermore, HC067047 (1 µmol/L) and BAPTA/AM (20 µmol/L), an [Ca 2+ ] i chelator, inhibited the GSK1016790A (100 nmol/L)-induced phosphorylation of cPLA 2 and PLA 2 activity ( Figure 2E and 2F) . ACh also increased the phosphorylation of cPLA 2 and PLA 2 activity in the HSD mice, and this was inhibited by HC067047 (1 µmol/L) and BAPTA/AM (20 µmol/L; Figure S5A and S5B). Notably, the basal level of [Ca 2+ ] i was higher in primary cultured MAECs from HSD mice ( Figure 3A) . Ionomycin, a selective calcium ionophore agent, increased phosphorylation of cPLA 2 in primary cultured MAECs from HSD mice ( Figure 3B ). Ionomycin also resulted in vascular contraction in aortas from HSD mice ( Figure 3C ), but its vehicle failed to induce vascular contraction. Moreover, in ex vivo cultured HSD mouse aortas, overexpression by adenoviral transduction Ad-EGFP-cPLA 2 (S505A), in which the phosphorylation site is mutated, suppressed the GSK1016790A-induced vascular contraction ( Figure 3D ).The successful transduction of Ad-EGFP-cPLA 2 (S505A) was demonstrated by the observation of EGFP (enhanced green fluorescent protein) fluorescence in the mouse aortas ( Figure S6 ). MAFP (methyl arachidonyl fluorophosphonate; 10 µmol/L), a cPLA 2 inhibitor, markedly reduced the GSK1016790A-induced vascular contraction in intact aortas isolated from HSD mice ( Figure  S7A ). The contractile response to ACh (10 µmol/L) was also suppressed in intact aortas isolated from HSD mice pretreated with MAFP (10 µmol/L; Figure S7B ). TRPV4-dependent and ACh-induced contractions were absent after the removal of extracellular Ca 2+ ( Figure S7C and S7D) . Together, these data demonstrate that TRPV4-dependent contractions are regulated by sustained Ca 2+ flux and the activation of cPLA 2 .
Role of COX Pathways in TRPV4-Dependent Contraction
As we had demonstrated that the contractile response to TRPV4 channel activation was cPLA 2 -dependent, we next explored the involvement of COX-derived prostanoid products. The expression of COX2 mRNA was significantly higher in aortas from HSD mice than those from NSD mice ( Figure 4A ). The COX2 protein expression was increased in aortas from HSD mice, consistent with the expression of COX2 mRNA ( Figure 4B ). In contrast, the expression of COX1 mRNA and protein did not differ between the 2 groups ( Figure 4A and 4B) . By exposing the aortas to the selective inhibitors of COX2, NS-398 (2 µmol/L), and Celecoxib (1 µmol/L), before addition of GSK1016790A, we found a marked inhibition of the TRPV4-dependent contraction ( Figure 4C ). Using the nonselective COX inhibitor indomethacin (1 µmol/L), we were able to abolish the TRPV4-dependent contractile response ( Figure 4D ). Similarly, in vessels treated with NS-398 (2 µmol/L), Celecoxib (1 µmol/L), or indomethacin (1 µmol/L), the contractile response to ACh (10 µmol/L) was significantly attenuated ( Figure 4E ). However, SC-506 (0.3 µmol/L), a selective inhibitor of COX1, slightly decreased GSK1016790A (100 nM) induced vascular contraction ( Figure S8 ).
PGF 2α as the EDCF
Having established that the TRPV4-dependent contractile response was because of the generation of COX2 products, we sought to identify the EDCF candidate for the contractile prostanoid being generated. Four possible candidates, 8-isoprostanes, thromboxane B 2 (TXB 2 ), prostaglandin E 2α (PGE 2 ), and PGF 2α were assayed by enzyme immunoassay. GSK1016790A (100 nmol/L) stimulated a marked rise in the release of PGF 2α , but not 8-isoprostanes, TXB 2 , and PGE 2 in aortas from HSD mice ( Figure 5A and B). Release of 8-isoprostanes, TXB 2 , PGE 2 , and PGF 2α was not affected by GSK1016790A (100 nmol/L) in aortas from NSD mice ( Figure 5A and B). The release of PGF 2α was also enhanced in aortas from L-NNA and Ang II mice induced by GSK1016790A (100 nmol/L; Figure 5B ).The release of PGF 2 α evoked by GSK1016790A (100 nmol/L) was significantly decreased by treatment with HC067047, MAFP, NS-398 (2 µmol/L), and removal of endothelium ( Figure 5C ). GSK1016790A did not induce the release of PGF 2α in the HSD TRPV4-KO mice ( Figure 5D ). Notably, ACh tended to induce more release of PGF 2α in aortas from HSD mice, and this was markedly attenuated by HC067047, MAFP, NS-398, and removal of endothelium ( Figure 5E ). The release of PGF 2α evoked by ACh was markedly inhibited in the HSD TRPV4-KO mice ( Figure 5F ). In the vascular tone study, we explored the role of PGF 2α in endothelium-dependent contraction. PGF 2α (10 ng/mL) induced contraction in aortas from HSD mice, and the contraction was reduced by S18886, a selective thromboxane receptor antagonist ( Figure S9A and  S9D) . Furthermore, GSK1016790A-and ACh-induced endothelium-dependent contractions were significantly reduced by S18886 in HSD mice ( Figure S9C and S9D) . Together, these data suggest that PGF 2α is the EDCF induced by TRPV4 activation.
Discussion
The major findings of this study are as follows: (1) TRPV4 regulated endothelium-dependent contractions in aortas from hypertensive mice, (2) cPLA 2 activation mediated TRPV4-dependent contraction, (3) in aortas from HSD mice, COX2 contributed to the regulation of TRPV4-and ACh-dependent contraction, and (4) PGF 2α was the EDCF induced by TRPV4 activation. Together, these data demonstrate an important pathological role of the TRPV4/cPLA 2 / COX2/PGF 2α signaling pathway in regulating contraction ( Figure 6 ).
Endothelium contributes in several ways to the local regulation of vascular function, and endothelium-dependent relaxation is impaired in the aortas of hypertensive rats. 6 Although endothelial TRPV4 channel activation is widely recognized to regulate vascular relaxation, contractile responses to TRPV4 channels have not yet been evaluated in models of diseases such as hypertension. In the present study, we demonstrated that in the hypertensive mouse aorta, activation of TRPV4 channels by GSK1016790A triggers a concentration-dependent contraction. We did not find a contractile response to GSK1016790A in the control groups. This TRPV4-dependent contractile response was abolished in hypertensive mouse aortic segments from which the endothelial cells had been mechanically removed. The contractile response to TRPV4 channel activation was also abrogated in the TRPV4-KO mouse. It is known from previous studies that endothelium-dependent contraction in response to ACh does not occur under normal physiological conditions but is observed under pathological conditions such as hypertension. 32, 33 Similar to previous findings in blood vessels, ACh triggered contraction in the HSD mouse aorta, and this contractile response was reversed by inhibition or deletion of TRPV4, thereby suggesting an involvement of TRPV4.
We next determined the role of the TRPV4 signaling pathway in regulating vascular contraction in HSD mice. To investigate a possible role of cPLA 2 in TRPV4-dependent contraction, we evaluated the phosphorylation of cPLA 2 Figure 5 . Prostaglandin F 2α (PGF 2α ) is the endothelium-derived contracting factor (EDCF) in TRPV4 (transient receptor potential vanilloid 4)-dependent contractions in aortas from high-salt diet (HSD) mice. A, Enzyme immunoassay (EIA) measurement of putative arachidonic acid metabolites 8-isoprostanes, thromboxane B 2 (TXB 2 ), prostaglandin E 2α (PGE 2 ), after exposure to GSK1016790A in aortas from HSD and normal-salt diet (NSD) mice. B, EIA measurement of putative arachidonic acid metabolites PGF 2α after exposure to GSK1016790A in aortas from mice with HSD, N ω -nitro-l-arginine (L-NNA), and angiotensin II (Ang II). C and D, Effects of different treatments and TRPV4 KO on GSK1016790A-stimulated release of PGF 2α . E and F, Effects of different treatments and TRPV4 KO on acetylcholine (ACh)-stimulated release of PGF 2α . Treatments: HC067047, MAFP (methyl arachidonyl fluorophosphonate), NS-398, and −Endo (without endothelium). Mean±SEM (n=4-6; **P<0.01 compared with no GSK1016790A or ACh; #P<0.05, ##P<0.01 compared with GSK or ACh group). KO indicates knockout; and WT, wild-type.
protein and PLA 2 activity, which are known to play key roles in generating the contractile COX agonist. 34, 35 We found that stimulation of TRPV4 with GSK1016790A (100 nmol/L) enhanced the phosphorylation of cPLA 2 and PLA 2 activity. Further studies using a cPLA 2 inhibitor revealed that treatment of aortas from HSD mice with MAFP resulted in decreased contractile responses to GSK and ACh. HC067047 and BAPTA/AM also inhibited the GSK1016790A-induced phosphorylation of cPLA 2 2 and resulted in vascular contraction in HSD mice. Moreover, overexpression of cPLA 2 (S505A) nearly abolished the effect of TRPV4-induced contraction. Therefore, the present data suggest that prolonged Ca 2+ influx through TRPV4 channels is crucial for the activation of cPLA 2 and contributes to endotheliumdependent contraction.
EDCFs, which mediate agonist-induced endotheliumdependent contraction, have been characterized as generated by the COX-mediated metabolism of arachidonic acid. 36 The 2 isoforms of COX, COX1 and COX2, are known to be constitutively expressed in endothelial cells and contribute to the generation of EDCFs depending on the type of blood vessel and pathological conditions. 8, 37 In this study, the contractile response to TRPV4 channel activation was mediated by COX2, as its expression was significantly higher in aortas from HSD-induced hypertensive mice, whereas the COX1 expression did not change. Our results agreed with the previous studies that COX2 expression is upregulated in arteries from spontaneously hypertensive rats and hypertensive patients. 38, 39 Increased oxidative stress in endothelium may serve a trigger to maintain enhanced COX2 expression in hypertensive animals. 38, 39 The selective inhibitors of COX2, NS-398, and Celecoxib, markedly attenuated the contractile responses to GSK and ACh. COX-dependent production of PGF 2α , 8-isoprostanes, TXB 2 , and PGE 2 can take place in endothelial cells. 36, 40 PGF 2α is involved in endothelium-dependent contractions in renovascular hypertensive rats. 39 Consist with this notion, we detected COX generation in response to TRPV4 activation in aortas, suggesting that TRPV4-dependent contraction is a PGF 2α -regulated response in hypertension. We further found that inhibitors of TRPV4, cPLA 2 , and COX2 decreased the generation of PGF 2α in response to TRPV4 activation and ACh. A previous study has noted that COX2-derived PGF 2α is the most likely EDCF candidate in aging aortas, which are sensitive to thromboxane. 10 Our results demonstrated that TRPV4-dependent contraction was derived from PGF 2α activation of thromboxane receptors in HSD-induced hypertension. The present results provided evidence for significantly greater TRPV4-dependent contractions in aortas from hypertensive mice than from normal mice. GSK1016790A and ACh were able to drive endothelium-dependent contractions in the absence of l-N G -nitroarginine methyl ester. However, GSK and ACh have been reported to trigger contractions in l-N Gnitroarginine methyl ester-treated aortas under physiological conditions. 27, 41 Therefore, our results suggest that hypertension might attenuate the bioavailability of nitric oxide, giving rise to endothelium-dependent contraction without adding l-N G -nitroarginine methyl ester. In conclusion, our study reveals a novel role of endothelial TRPV4 in mediating tone in the aorta of hypertensive mouse. The present data showed that TRPV4 regulated endothelium-dependent contractions through activation of cPLA 2 and COX2 in aortas from HSD mice. We also found that PGF 2α was the EDCF induced by TRPV4 activation. Our study reveals a novel role for TRPV4 in hypertension and for TRPV4-mediated Ca 2+ influx in the activation of cPLA 2 and COX2.
Perspectives
EDCFs regulate vascular tone and blood pressure and their release is disturbed in hypertension. In this study, we uncovered a novel role of endothelial TRPV4 channels in mediating tone in the aorta of hypertensive mouse. Our data showed that TRPV4 regulates endothelium-dependent contraction through activation of cPLA 2 and COX2 in aortas from HSD mice. We also found that PGF 2α is the EDCF induced by TRPV4 activation. Our study reveals a novel role for TRPV4 in hypertension and for TRPV4-mediated Ca 2+ influx in the activation of cPLA 2 and COX2. In future, it would be interesting to investigate the pathological role of enhanced TRPV4/cPLA 2 /COX2/PGF 2α signaling in human hypertension. ] i , resulting in activation of cytosolic cPLA 2 (phospholipase A 2 ) and the subsequent activation of the COX2 (cyclooxygenase 2), then leading to the generation of prostaglandin F 2α (PGF 2α ), the most likely candidate of endothelium-derived contracting factor (EDCF), thus causes vascular contraction. AA indicates arachidonic acid. 
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